Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1939 1
1946 1
1954 1
1957 1
1964 3
1965 4
1966 7
1967 6
1968 8
1969 10
1970 5
1971 2
1972 3
1973 2
1974 4
1975 2
1976 8
1977 9
1978 5
1979 5
1980 10
1981 13
1982 10
1983 11
1984 9
1985 4
1986 11
1987 8
1988 8
1989 15
1990 9
1991 14
1992 9
1993 21
1994 18
1995 15
1996 13
1997 13
1998 14
1999 20
2000 21
2001 21
2002 13
2003 20
2004 23
2005 12
2006 16
2007 15
2008 20
2009 13
2010 25
2011 25
2012 22
2013 20
2014 25
2015 27
2016 33
2017 33
2018 36
2019 33
2020 48
2021 38
2022 28
2023 35
2024 31
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

906 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group. Verma S, et al. Among authors: miles d. N Engl J Med. 2012 Nov 8;367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1. N Engl J Med. 2012. PMID: 23020162 Free PMC article. Clinical Trial.
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131 investigators. Miles D, et al. Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1. Ann Oncol. 2021. PMID: 34219000 Free article. Clinical Trial.
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. Diéras V, et al. Among authors: miles d. Lancet Oncol. 2017 Jun;18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1. Epub 2017 May 16. Lancet Oncol. 2017. PMID: 28526536 Free PMC article. Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
Deng R, Gibiansky L, Lu T, Flowers CR, Sehn LH, Liu Q, Agarwal P, Liao MZ, Dere R, Lee C, Man G, Hirata J, Li C, Miles D. Deng R, et al. Among authors: miles d. CPT Pharmacometrics Syst Pharmacol. 2024 Jun;13(6):1055-1066. doi: 10.1002/psp4.13141. Epub 2024 Apr 15. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38622879 Free PMC article. Clinical Trial.
Germ cell sex and cell cycle.
Miles DC, Western PS. Miles DC, et al. Histol Histopathol. 2012 Apr;27(4):445-57. doi: 10.14670/HH-27.445. Histol Histopathol. 2012. PMID: 22374722 Review.
Benign neonatal seizures.
Miles DK, Holmes GL. Miles DK, et al. J Clin Neurophysiol. 1990 Jul;7(3):369-79. doi: 10.1097/00004691-199007000-00004. J Clin Neurophysiol. 1990. PMID: 2211994 Review.
906 results